Free shipping on all orders over $ 500

Denintuzumab-MMAF

Cat. No. M58983

All AbMole products are for research use only, cannot be used for human consumption.

Denintuzumab-MMAF Structure
Synonym:

Anti-CD19 Reference Antibody

Size Price Availability Quantity
100ug USD 480  USD480 In stock
1mg USD 1280  USD1280 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
  • Purity: >99%, Endotoxin < 1 EU/µg
  • COA
  • MSDS
Biological Activity

Denintuzumab-MMAF is an antibody-drug conjugate (ADC). Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3). Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. Denintuzumab can be used in the research of acute lymphoblastic leukemia.

Immobilized human EGFR His at 2 ug/mL can bind denintuzumab-MMAF, the EC50 is 0.01985 ug/mL.

Chemical Information
Solubility (25°C) For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml.
Storage Store at ≤ -20℃ for up to 24 months. Avoid repeated freeze-thaw cycles.
Related Antibody-Drug Conjugates (ADCs) Products
Glembatumumab vedotin

Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate (ADC) comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects.

Enapotamab vedotin

Enapotamab vedotin is an AXL-targeted antibody-drug conjugate (ADC) with inhibitory potential against high AXL expressing non-small cell lung cancer (NSCLC).

Codrituzumab-MMAE (CHO)

Codrituzumab-MMAE is an antibody-drug conjugate (ADC). Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3).

Tisotumab Vedotin

Tisotumab Vedotin is a tissue factor-directed antibody-drug conjugate (ADC) containing a tissue factor-specific fully human monoclonal antibody (TF-011) conjugated to monomethylmethane auristatin E (MMAE), which can be used in studies related to cervical cancer.

Vandortuzumab vedotin

Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug-conjugate to target prostate cancer.

  Catalog
Abmole Inhibitor Catalog




Keywords: Denintuzumab-MMAF, Anti-CD19 Reference Antibody supplier, Antibody-Drug Conjugates (ADCs), inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.